Skip to main content
. 2014 May 9;7(5):384–390. doi: 10.1111/cts.12162

Figure 3.

Figure 3

Overall survival (OS) in the DLBCL patients treated with rituximab. (A) OS is significantly longer in patients treated with rituximab in addition to the standard chemotherapy; (B) patients with methylated p15 tended to have longer OS than patients with unmethylated p15 gene; (C) female patients with methylated p15 had significantly longer OS than those with unmethylated p15 gene; (D) patients with no bulky tumor mass with methylated p15 had significantly longer OS than those with unmethylated p15 gene.